[1]
Corvol JC,Mariani LL, [Therapeutic and pharmacologic perspectives in Parkinson's disease]. La Revue du praticien. 2018 May; [PubMed PMID: 30869416]
[2]
Ebada MA,Alkanj S,Ebada M,Abdelkarim AH,Diab A,Aziz MAE,Soliman AM,Fayed N,Bahbah EI,Negida A, Safety and Efficacy of Levetiracetam for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review. CNS [PubMed PMID: 30868968]
[3]
Romagnolo A,Merola A,Artusi CA,Rizzone MG,Zibetti M,Lopiano L, Levodopa-Induced Neuropathy: A Systematic Review. Movement disorders clinical practice. 2019 Feb; [PubMed PMID: 30838307]
[4]
Aurora RN,Kristo DA,Bista SR,Rowley JA,Zak RS,Casey KR,Lamm CI,Tracy SL,Rosenberg RS, The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012 Aug 1; [PubMed PMID: 22851801]
[6]
Ogungbenro K,Pertinez H,Aarons L, Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying. The AAPS journal. 2015 Jan [PubMed PMID: 25413723]
[7]
Dhall R,Kreitzman DL, Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 5 [PubMed PMID: 27044646]
[8]
Ondo WG,Shinawi L,Moore S, Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Movement disorders : official journal of the Movement Disorder Society. 2010 Dec 15 [PubMed PMID: 20925074]
[9]
Rizek P,Kumar N,Jog MS, An update on the diagnosis and treatment of Parkinson disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2016 Nov 1 [PubMed PMID: 27221269]
[10]
Patel T,Chang F, Parkinson's disease guidelines for pharmacists. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2014 May [PubMed PMID: 24847369]
[11]
LeWitt PA,Hauser RA,Pahwa R,Isaacson SH,Fernandez HH,Lew M,Saint-Hilaire M,Pourcher E,Lopez-Manzanares L,Waters C,Rudzínska M,Sedkov A,Batycky R,Oh C, Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Neurology. 2019 Feb [PubMed PMID: 30663606]
[12]
Trenkwalder C,Kuoppamäki M,Vahteristo M,Müller T,Ellmén J, Increased dose of carbidopa with levodopa and entacapone improves [PubMed PMID: 30824559]
[13]
Poewe W,Chaudhuri KR,Bergmann L,Antonini A, Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegenerative disease management. 2019 Feb; [PubMed PMID: 30547712]
[14]
Patel AB,Jimenez-Shahed J, Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date. Neuropsychiatric disease and treatment. 2018; [PubMed PMID: 30464480]
[16]
Kalinderi K,Papaliagkas V,Fidani L, Pharmacogenetics and levodopa induced motor complications. The International journal of neuroscience. 2019 Apr; [PubMed PMID: 30359152]
[17]
Bougea A,Spantideas N,Katoulis A,Stefanis L, Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach. Acta neurologica Belgica. 2019 Sep [PubMed PMID: 31338806]
[18]
Fabbri M,Rosa MM,Ferreira JJ, Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach. Drugs [PubMed PMID: 30318555]
[19]
Classen J,Koschel J,Oehlwein C,Seppi K,Urban P,Winkler C,Wüllner U,Storch A, Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. Journal of neural transmission (Vienna, Austria : 1996). 2017 Aug; [PubMed PMID: 28702850]